Psyence Biomedical Ltd.
PBM
$1.69
$0.116.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 31.47% | 5.74% | |||
| Depreciation & Amortization | 0.00% | 8.33% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.46% | 39.94% | |||
| Operating Income | -24.46% | -39.94% | |||
| Income Before Tax | 24.40% | -2.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.40% | -2.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.40% | -2.26% | |||
| EBIT | -24.46% | -39.94% | |||
| EBITDA | -24.48% | -39.98% | |||
| EPS Basic | 45.94% | 65.53% | |||
| Normalized Basic EPS | 11.70% | 48.95% | |||
| EPS Diluted | 45.77% | 65.53% | |||
| Normalized Diluted EPS | 11.70% | 48.95% | |||
| Average Basic Shares Outstanding | 39.84% | 196.67% | |||
| Average Diluted Shares Outstanding | 39.84% | 196.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||